BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT06322394
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
- Registry
-
NCT06322394
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06322394. Randomized; double masking; primary purpose treatment. Start 2024-02-07 (actual); primary completion 2025-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- high-dose BXOS110
- Intervention (Drug)
- low-dose BXOS110
- Intervention (Drug)
- Placebo
- Lead sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Record details
- Record id
cardio:ct-nct06322394- Content hash
de8b626a9a56c0a0582e6c1b66d476e325793a6d36d95540ed69d1166dd899f3